Drug Profile
ITV 1
Alternative Names: Immune therapeutic vaccine-1; ImmunH; Inactivated pepsin fraction HIV vaccine; IPF-ITV Phases; IPF-ITV-1; Irreversible pepsin fraction HIV vaccine; ITV-1Latest Information Update: 24 Sep 2020
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer Immunotech Laboratories
- Class AIDS vaccines; Antivirals; Peptide vaccines
- Mechanism of Action HIV envelope protein gp120 inhibitors; HIV envelope protein gp41 inhibitors; HIV fusion inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV infections
- Phase II Hepatitis C
Most Recent Events
- 24 Sep 2020 Launched for HIV infections in Bulgaria (Parenteral) before September 2020 (Immunotech Laboratories website, September 2020)
- 28 Jan 2018 No recent reports of development identified for clinical-Phase-Unknown development in HIV-infections in South Africa (Parenteral, Suspension)
- 22 Jun 2017 Immunotech Laboratories anticipates to complete the validation documentation and registration process for the manufacture of ITV 1 and submit an application to the Bulgarian Drug Administration by the end of September 2017